Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
评估Amicus Therapeutics：来自6位金融分析师的见解
6 analysts have expressed a variety of opinions on Amicus Therapeutics (NASDAQ:FOLD) over the past quarter, offering a diverse set of opinions from bullish to bearish.
在过去的一个季度中，有6位分析师对Amicus Therapeutics（纳斯达克股票代码：FOLD）表达了各种看法，从看涨到看跌，提出了各种各样的观点。
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
下表简要介绍了他们最近的评级，展示了过去30天情绪的演变，并将其与前几个月进行了比较。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $17.5, a high estimate of $22.00, and a low estimate of $13.00. A decline of 6.67% from the prior average price target is evident in the current average.
分析师通过对12个月目标股价的评估提供了更深入的见解，显示平均目标价为17.5美元，最高估计为22.00美元，低估值为13.00美元。目前的平均价格比先前的平均目标股价下降了6.67％。
Deciphering Analyst Ratings: An In-Depth Analysis
解密分析师评级：深度分析
The...
通...
登录免费看全文
登录/注册
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。